We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Accelerating Biomarker Discovery and Disease Research with Tecan’s Automated Hybridization Stations

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Protagen AG announces that it relies on two Tecan HS 4800™ Pro Hybridization Stations for automated processing of its UNIchip® protein arrays for antibody characterization, and for discovery of biomarkers relevant to diseases such as multiple sclerosis, rheumatoid arthritis and cancer indications.

“After we have found a set of putative biomarkers, the crucial step forward is to test them in quantitative terms in larger patient cohorts, and this requires a highly reproducible chip processing procedure,” explained Dr Jens Beator, Director of the Protein Biochips business unit at Protagen. “Each chip usually includes a few hundred biomarkers that need to be quantified in a single assay. Careful standardization is extremely important for reproducible analysis so we always process all of our chips under identical conditions using the HS 4800 Pro Hybridization Stations.”

“It was relatively straightforward to optimize the assay for automation and to develop standard operating procedures, we also had good support from Tecan,” Jens continued. “In the past we had to perform the assays manually, which required many man hours from our technicians but now those staff are free to do other work.”